Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Heme/Lymph 2 > Managing Chemo Complications - Fitz > Flashcards

Managing Chemo Complications - Fitz Flashcards

1
Q

CHOP regimen

A

NHL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ABVD regimen

A

HL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

2 main ways to cause N/V from chemo

A
  • Direct activation of medullary CTZ

- 5-HT3 release via damaged enterochromaffin cells (GI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

-setron

Use?

A

5-HT3 receptor antagonists

Acute CINV - PRIMARY THERAPY FOR THIS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Metoclopramide

Use?

A

D2 (central) receptor antagonist

Acute CINV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

-pitant

Use?

A

Neurokinin-1 receptor antagonists

Acute or delayed CINV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Dronabinol

Use?

A

Cannabinoid CB1 receptor agonist

Refractory CINV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Side effect of -setron

A

QT prolongation (EKG changes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Aprepitant blocks the binding of what substance?

A

Substance P (to the NK1 receptor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Delayed emesis is most common after what?

Treatment?

A

Cisplatin

Aprepitant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Receptors in the CTZ

A

5HT-3, D2, NK1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Receptors in the vagal afferent (associated w/ N/V)

A

5HT-3, NK1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Which of the 3 receptor blockers does NOT act on vagal afferents?

A

Metoclopramide (D2 receptor antagonist)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Treatment regimen for high CINV risk

A

-setron, Aprepitant, Dexamethasone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Treatment regimen for moderate CINV risk

A

-setron, Dexamethasone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Treatment regimen for low CINV risk

A

Dexamethasone

17
Q

Treatment for anticipatory emesis

MoA

A

Benzo (Lorazepam)

GABA-A receptor (Cl- channel) agonist/potentiator = hyperpolarization, relaxation

18
Q

Treatment for Cyclophosphamide-induced hemorrhagic cystitis

MoA and when?

A

MESNA

PROPHYLACTIC anti-toxin for acrolein

19
Q

Side effects of MESNA

A

Hypersensitivity, bad sulfur smell (GI distress)

20
Q

Dexrasoxane

MoA

A

Blunting agent for Doxorubicin cardiotoxicity

Chelates iron-induced free radicals

21
Q

Amifostine

MoA

Requires what?

A

Blunting agent for Cisplatin nephrotoxicity

Chelates toxic metabolites and ROS

Activation by alkaline phosphatase

Heme/Lymph 2 (16 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions